Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Total Current Liabilities (2016 - 2025)

Anaptysbio's Total Current Liabilities history spans 10 years, with the latest figure at $38.6 million for Q4 2025.

  • For Q4 2025, Total Current Liabilities fell 14.98% year-over-year to $38.6 million; the TTM value through Dec 2025 reached $38.6 million, down 14.98%, while the annual FY2025 figure was $38.6 million, 14.98% down from the prior year.
  • Total Current Liabilities reached $38.6 million in Q4 2025 per ANAB's latest filing, up from $38.1 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $45.4 million in Q4 2024 to a low of $14.5 million in Q1 2021.
  • Average Total Current Liabilities over 5 years is $31.6 million, with a median of $35.7 million recorded in 2023.
  • Peak YoY movement for Total Current Liabilities: plummeted 37.74% in 2021, then soared 109.51% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $16.1 million in 2021, then skyrocketed by 61.84% to $26.1 million in 2022, then skyrocketed by 43.71% to $37.4 million in 2023, then rose by 21.33% to $45.4 million in 2024, then decreased by 14.98% to $38.6 million in 2025.
  • Per Business Quant, the three most recent readings for ANAB's Total Current Liabilities are $38.6 million (Q4 2025), $38.1 million (Q3 2025), and $35.5 million (Q2 2025).